Arnold J H, Truog R D, Orav E J, Scavone J M, Hershenson M B
Department of Anesthesia, Children's Hospital, Boston, Massachusetts 02115.
Anesthesiology. 1990 Dec;73(6):1136-40. doi: 10.1097/00000542-199012000-00011.
We undertook a retrospective chart review of 37 neonates who received fentanyl by continuous infusion while undergoing extracorporeal membrane oxygenation (ECMO) between May 1986 and October 1988. We quantified the doses of all sedatives utilized, determined the incidence of neonatal abstinence syndrome (NAS), and identified risk factors associated with NAS. We determined peak fentanyl infusion rate, mean fentanyl infusion rate, total fentanyl dose, and duration of ECMO therapy. NAS was observed in 21 of 37 neonates (57%). In both the NAS and non-NAS neonates, mean infusion rate increased steadily during ECMO therapy, from a mean of 11.6 +/- 6.9 (SD) micrograms.kg-1.h-1 on day 1 to a mean of 52.5 +/- 19.4 (SD) micrograms.kg-1.h-1 by day 8. Total fentanyl dose and duration of ECMO were significantly greater in neonates with NAS. We found that neonates with a total dose greater than 1.6 mg/kg or an ECMO duration greater than 5 days had a significantly greater incidence of NAS (chi-squared test, P less than 0.01 and P less than 0.005; odds ratios = 7.0 and 13.9, respectively). With multiple logistic regression, ECMO duration was found to be the most powerful predictor of the occurrence of NAS. We also measured plasma fentanyl concentrations in a separate group of 5 neonates receiving fentanyl by continuous infusion for sedation. Fentanyl concentrations increased steadily during the period of infusion, suggesting the development of tolerance to the sedating effects. We conclude that continuous administration of fentanyl for sedation is associated with the uniform development of tolerance and a significant incidence of dependence. Alternative approaches to sedation should be investigated.
我们对1986年5月至1988年10月期间在接受体外膜肺氧合(ECMO)治疗时通过持续输注接受芬太尼的37例新生儿进行了回顾性病历审查。我们对所有使用的镇静剂剂量进行了量化,确定了新生儿戒断综合征(NAS)的发生率,并确定了与NAS相关的危险因素。我们确定了芬太尼输注峰值速率、平均芬太尼输注速率、芬太尼总剂量以及ECMO治疗持续时间。在37例新生儿中有21例(57%)观察到NAS。在NAS和非NAS新生儿中,ECMO治疗期间平均输注速率均稳步增加,从第1天的平均11.6±6.9(标准差)微克·千克⁻¹·小时⁻¹增加到第8天的平均52.5±19.4(标准差)微克·千克⁻¹·小时⁻¹。NAS新生儿的芬太尼总剂量和ECMO持续时间显著更长。我们发现,芬太尼总剂量大于1.6mg/kg或ECMO持续时间大于5天的新生儿NAS发生率显著更高(卡方检验,P<0.01和P<0.005;优势比分别为7.0和13.9)。通过多因素逻辑回归分析,发现ECMO持续时间是NAS发生的最有力预测因素。我们还在另一组通过持续输注接受芬太尼镇静的5例新生儿中测量了血浆芬太尼浓度。输注期间芬太尼浓度稳步增加,提示对镇静作用产生了耐受性。我们得出结论,持续输注芬太尼进行镇静与耐受性的普遍形成和显著的依赖发生率相关。应研究替代的镇静方法。